Fagan Associates’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $11.7M | Sell |
26,195
-90
| -0.3% | -$40.1K | 1.8% | 15 |
|
|
2025
Q1 | $12.7M | Sell |
26,285
-233
| -0.9% | -$113K | 2.13% | 13 |
|
|
2024
Q4 | $10.7M | Buy |
26,518
+93
| +0.4% | +$37.5K | 1.7% | 14 |
|
|
2024
Q3 | $12.3M | Sell |
26,425
-70
| -0.3% | -$32.6K | 2.06% | 10 |
|
|
2024
Q2 | $12.4M | Buy |
26,495
+557
| +2% | +$261K | 2.17% | 9 |
|
|
2024
Q1 | $10.8M | Buy |
25,938
+496
| +2% | +$207K | 2.03% | 12 |
|
|
2023
Q4 | $10.4M | Buy |
25,442
+355
| +1% | +$144K | 2.25% | 10 |
|
|
2023
Q3 | $8.72M | Buy |
25,087
+510
| +2% | +$177K | 2.11% | 13 |
|
|
2023
Q2 | $8.65M | Buy |
24,577
+433
| +2% | +$152K | 2.1% | 14 |
|
|
2023
Q1 | $7.61M | Sell |
24,144
-97
| -0.4% | -$30.6K | 1.89% | 16 |
|
|
2022
Q4 | $7M | Buy |
24,241
+250
| +1% | +$72.2K | 1.87% | 15 |
|
|
2022
Q3 | $6.95M | Buy |
23,991
+270
| +1% | +$78.2K | 1.94% | 11 |
|
|
2022
Q2 | $6.68M | Sell |
23,721
-2,178
| -8% | -$614K | 1.79% | 18 |
|
|
2022
Q1 | $6.76M | Buy |
25,899
+2,480
| +11% | +$647K | 1.39% | 23 |
|
|
2021
Q4 | $5.14M | Buy |
23,419
+3,012
| +15% | +$661K | 0.98% | 27 |
|
|
2021
Q3 | $3.7M | Sell |
20,407
-1,035
| -5% | -$188K | 0.8% | 38 |
|
|
2021
Q2 | $4.32M | Buy |
21,442
+3,157
| +17% | +$636K | 0.92% | 33 |
|
|
2021
Q1 | $3.93M | Buy |
18,285
+14,570
| +392% | +$3.13M | 0.92% | 33 |
|
|
2020
Q4 | $878K | Buy |
+3,715
| New | +$878K | 0.22% | 69 |
|